Kelly Barker
Family Medicine · Scottsdale, AZNPI 1336373919
Payments from drug & device makers
Across 85 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$805
- Amgen$172
- Novo Nordisk$158
- Abbott$101
- Lilly USA, LLC$94
- Phathom Pharmaceuticals, Inc.$64
- plus $436 from 14 others
What the payments were for
- Food & beverage$1,80599%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $805 |
| Amgen | 8 | $172 |
| Novo Nordisk | 8 | $158 |
| Abbott | 4 | $101 |
| Lilly USA, LLC | 6 | $94 |
| Phathom Pharmaceuticals, Inc. | 2 | $64 |
| Novartis | 2 | $55 |
| Inspire Medical Systems, Inc. | 1 | $47 |
| Cleerly, Inc. | 1 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Currax Pharmaceuticals LLC | 2 | $41 |
| Pfizer | 2 | $39 |
| Boehringer Ingelheim | 1 | $30 |
| Exact Sciences | 1 | $27 |
| Boston Scientific | 1 | $24 |
| Arbor Pharmaceuticals, Inc. | 2 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| GSK | 1 | $17 |
| Bausch Health US, LLC | 1 | $14 |
| AstraZeneca | 1 | $11 |
How this compares
$1,830 in reported general payments places this provider in the 80th percentile of 2,099 family medicine providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 36 | $56,402 |
| MounjaroTirzepatide | 48 | $52,254 |
| Dupixent PenDupilumab | 11 | $41,162 |
| OzempicSemaglutide | 11 | $22,949 |
| XareltoRivaroxaban | 24 | $22,095 |
| JardianceEmpagliflozin | 12 | $20,067 |
| UbrelvyUbrogepant | 13 | $13,122 |
| Praluent PenAlirocumab | 13 | $6,673 |
| SynthroidLevothyroxine Sodium | 38 | $3,188 |
| Zolpidem Tartrate | 27 | $2,352 |
| Levothyroxine Sodium | 154 | $1,612 |
| Rosuvastatin Calcium | 90 | $1,280 |
| Liothyronine Sodium | 23 | $1,236 |
| ProgesteroneProgesterone, Micronized | 23 | $994 |
| Duloxetine Hcl | 43 | $883 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $94 | $108,65684 claims |
| Novo NordiskOzempic | $158 | $22,94911 claims |
| Boehringer IngelheimJardiance | $30 | $20,06712 claims |
| AbbVieUbrelvy, Synthroid | $805 | $16,31051 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Scottsdale
- Danielle ArmasScottsdale$73M
- Joseph LilloScottsdale$6.3M
- Sam FereidouniScottsdale$486K
- Casey MyersScottsdale$246K
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
- Corey AndersonMesa$21.5M
- Dena PetersenTucson$14.7M
- Gerald ShockeyMesa$12.3M
- Brock MerrittPhoenix$8.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.